AstraZeneca shares fall after US FDA panel rejection
Shares of AstraZeneca fell 1.7 percent on Friday after a U.S. FDA advisory panel voted against its experimental breast cancer drug during an overnight session.
Xurve View
Insights:
Xurve View
ASTRAZENECA PLC shares fell 1.7% on May 1 after a United States regulatory panel rejected its experimental breast cancer treatment. The United Kingdom drugmaker faced the negative vote overnight following a review of the drug's clinical data. This rejection stalls a key oncology pipeline asset, pressuring growth targets for the firm's dominant cancer portfolio.
